The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.

For information, the company have announced that the trial for pembrolizumab plus lenvatinib in endometrial cancer did not meet its primary endpoint and therefore they will no longer be pursuing a ...

The price you pay for Lenvima may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

Twenty-nine and 34 percent of patients in the TACE with lenvatinib plus pembrolizumab and TACE plus placebo groups died, with 24-month overall survival rates of 75 and 69 percent, respectively ...

Dana Walker, vice president, Opdivo global programme lead, BMS, said: “HCC is the predominant type of liver cancer globally, including in the EU, and when diagnosed at the advanced or unresectable ...

This landmark trial demonstrates that the novel combination of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) significantly improves progression-free survival compared to ...

Efficacy and safety of endoscopic retrograde cholangiopancreatography (ERCP) vs percutaneous transhepatic biliary drainage (PTBD) for cholangiocarcinoma biliary obstruction: An updated systematic ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve statistical significance for overall survival in patients with advanced ...

Phase I/Ib study of afatinib with capecitabine in patients with refractory solid tumors and pancreaticobiliary cancers. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...